Skip to main content
Clinical Trials/NCT01032044
NCT01032044
Completed
Not Applicable

Confocal Laser Endomicroscopy for Assessment of Neoplasia After Mucosal Ablation or Resection of Gastrointestinal Neoplasia

Mauna Kea Technologies6 sites in 3 countries164 target enrollmentFebruary 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Barrett Syndrome
Sponsor
Mauna Kea Technologies
Enrollment
164
Locations
6
Primary Endpoint
Number of Barrett's Esophagus (BE) Participants With a Composite Outcome of "Optimally Treated"
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

This study focuses on demonstrating the value of probe-based Confocal Laser Endomicroscopy (pCLE) in guiding endoscopic therapeutic procedures in Barrett's Esophagus (BE).

It is a randomized controlled outcomes study including patients already treated for Barrett's Esophagus lesion(s) and undergoing high definition white light endoscopy follow up procedure, with or without pCLE (2 arms will be considered in this study). The procedures will be carried out per standards of practice with appropriately trained physicians.

Detailed Description

It is a randomized controlled outcomes study including patients already treated for Barrett's Esophagus lesion(s) and undergoing high definition white light endoscopy follow up procedure, with or without pCLE guided evaluation (2 arms will be considered in this study). The procedures will be carried out per standards of practice with appropriately trained physicians.

Registry
clinicaltrials.gov
Start Date
February 2010
End Date
April 2011
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with BE with Intestinal Metaplasia, Low Grade-IntraEpithelial Neoplasia/High Grade-IntraEpithelial Neoplasia as the original indication for ablative treatment.
  • Undergoing any type of endoscopic BE ablation treatment
  • \<2cm of circumferential BE and \<5 total islands of BE on prior to last ablation.
  • Age \> 18 years
  • Ability to provide written, informed consent

Exclusion Criteria

  • Participation in another clinical study
  • Circumferential BE
  • Complete eradication of BE documented by biopsies
  • Inability to obtain biopsies due to anticoagulation, varices, etc.
  • Allergy to fluorescein
  • Pregnancy
  • Renal insufficiency

Outcomes

Primary Outcomes

Number of Barrett's Esophagus (BE) Participants With a Composite Outcome of "Optimally Treated"

Time Frame: 3 month follow-up endoscopic procedure

Number of Barrett's Esophagus (BE) Participants with a Composite Outcome of "Optimally Treated", in each group defined as patients for whom all lesions are ablated when disease is present, or not ablated when disease is absent, or have complete ablation of all disease at the 3 month follow-up.

Study Sites (6)

Loading locations...

Similar Trials